Callan Family Office, LLC
Family OfficePosition in ATNM — Actinium Pharmaceuticals, Inc.
CIK 1938970
RADNOR, PA
Position in ATNM
as of Mar 31, 2026
· filed May 13, 2026
Position Value
$11,884
-$20,216 QoQ
Shares Held
11,944
-49.4% QoQ
Ownership
0.038%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2025
5 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ATNM Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Callan Family Office, LLC holds $25,981,974 across 28 Biotechnology names. ATNM ranks #28 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | REGN |
Regeneron Pharmaceuticals, Inc.
|
9,036 | $6,981,575 | |
| 2 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
15,262 | $6,815,093 | |
| 3 | GMAB |
Genmab A/S
|
55,047 | $1,476,911 | |
| 4 | ARGX |
Argenx SE
|
1,977 | $1,443,704 | |
| 5 | JAZZ |
Jazz Pharmaceuticals plc
|
7,358 | $1,391,029 | |
| 6 | TECH |
BIO-TECHNE Corp
|
20,483 | $1,070,441 | |
| 7 | INCY |
Incyte Corp
|
11,135 | $1,048,026 | |
| 8 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
3,035 | $1,004,190 |
All Filings in ATNM
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $11,884 | 11,944 | Shares | Sole | 2026-05-13 | |
| 2025-12-31 | $32,100 | 23,603 | Shares | Sole | 2026-02-12 | |
| 2025-09-30 | $37,764 | 23,603 | Shares | Sole | 2025-11-04 | |
| 2025-06-30 | $33,044 | 23,603 | Shares | Sole | 2025-07-24 | |
| 2025-03-31 | $38,000 | 23,603 | Shares | Sole | 2025-05-13 | |
| No filing history on record for this holder in this stock. | ||||||